US 10,889,808 B2
CRISPR-associated (CAS) protein
Matthew Merrill Carter, Berkeley, CA (US); and Paul Daniel Donohoue, Berkeley, CA (US)
Assigned to Locanabio, Inc., San Diego, CA (US)
Filed by Locana, Inc., San Diego, CA (US)
Filed on Mar. 3, 2019, as Appl. No. 16/290,957.
Application 16/290,957 is a continuation of application No. 15/937,840, filed on Mar. 27, 2018.
Claims priority of provisional application 62/629,641, filed on Feb. 12, 2018.
Claims priority of provisional application 62/477,494, filed on Mar. 28, 2017.
Prior Publication US 2019/0185831 A1, Jun. 20, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/1136 (2013.01); C12N 15/85 (2013.01); C12N 2310/20 (2017.05); C12N 2800/22 (2013.01)] 27 Claims
 
1. An expression cassette comprising:
a polynucleotide encoding:
a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein, wherein the Cas protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:44, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:37, an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:39, and an amino acid sequence having at least 98 percent sequence identity to SEQ ID NO:44; the polynucleotide is operably linked to a regulatory sequence; and
one or more cognate nucleic acid guides, wherein the one or more cognate nucleic acid guides comprise a repeat sequence and a spacer sequence, wherein the repeat sequence and the spacer sequence do not naturally occur together, wherein the Cas protein is capable of forming one or more nucleoprotein complexes with the one or more cognate nucleic acid guides, and wherein each nucleoprotein complex is capable of site-directed binding to a target nucleic acid sequence.